Collateral for a security interest recorded Apr 8, 2026 (Royal Bank of Canada).
Term ends Dec 7, 2026 · High confidence
20-year base term ended Mar 10, 2026
Held by Gen-Probe Incorporated
Filed Mar 10, 2006 as application 11/372,218 · Granted Jun 16, 2009
Base term plus 272 days of patent term adjustment (USPTO delay)
Today
2006
2026
Clock starts
Mar 10, 2006
Mar 10, 2006
Term ends
Dec 7, 2026
Dec 7, 2026
Granted
Jun 16, 2009
Jun 16, 2009
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
272
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
This patent's term runs 272 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 10, 2006, when this application, 11/372,218, was filed | Mar 10, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +272 days, USPTO patent term adjustment record | Dec 7, 2026 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 7, 2026 | High confidence |
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Feb 14, 2007 Reel 18889, frame 626 | Light, James P. | Gen-Probe Incorporated | Assignment of Assignor's Interest |
| Aug 1, 2012 Reel 28810, frame 745 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Goldman Sachs Bank USA | Security Agreement |
| Jun 4, 2015 Reel 35820, frame 239 | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc. | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Biolucent, LLC | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Corporation | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Surgical Products, Limited Partnership | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Suros Surgical Systems, Inc. | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Third Wave Technologies, Inc. | Security Interest Release Reel/Frame 028810/0745 |
| Jun 4, 2015 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Gen-Probe Incorporated | Security Interest Release Reel/Frame 028810/0745 |
| Aug 7, 2015 Reel 36307, frame 199 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Direct Radiography Corp.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc. | Bank of America, N.A., as Collateral Agent | Security Agreement |
| Nov 9, 2017 Reel 44432, frame 565 | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Goldman Sachs Bank USA | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 028810 Frame: 0745. Assignor(S) Hereby Confirms the Security Agreement. |
| Nov 9, 2017 Reel 44727, frame 529 | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc.; Biolucent, LLC; Cytyc Corporation; Cytyc Surgical Products, Limited Partnership; Suros Surgical Systems, Inc.; Third Wave Technologies, Inc.; Gen-Probe Incorporated | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Hologic, Inc. | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Biolucent, LLC | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Corporation | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Cytyc Surgical Products, Limited Partnership | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Suros Surgical Systems, Inc. | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Third Wave Technologies, Inc. | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Nov 9, 2017 reel/frame not recorded | Goldman Sachs Bank USA, as Collateral Agent | Gen-Probe Incorporated | Corrective Assignment to Correct the Incorrect Patent No. 8081301 Previously Recorded at Reel: 035820 Frame: 0239. Assignor(S) Hereby Confirms the Security Interest Release. |
| Apr 8, 2026 Reel 75462, frame 440 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Royal Bank of Canada, as Collateral Agent | Security Interest |
| Apr 8, 2026 Reel 75926, frame 339 | Biotheranostics, Inc.; Gen-Probe Incorporated; Gen-Probe Prodesse, Inc.; Cytyc Corporation; Suros Surgical Systems, Inc.; Gynesonics, Inc.; Bolder Surgical, LLC; Faxitron Bioptics, LLC; Health Beacons, Inc.; Hologic, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
| Apr 28, 2026 Reel 75566, frame 39 | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp.; Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC; Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership; Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc.; Gen-Probe Prodesse, Inc.; Suros Surgical Systems, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Hologic, Inc., on Its Own Behalf and as Successor-by-Merger to Direct Radiography Corp. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Corporation, on Its Own Behalf and as Successor-by-Merger to Biolucent, LLC | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Cytyc Surgical Products, LLC, as Successor-by-Conversion to Cytyc Surgical Products, Limited Partnership | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Incorporated, on Its Own Behalf and as Successor-by-Merger to Third Wave Technologies, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Gen-Probe Prodesse, Inc. | Release of Security Interest |
| Apr 28, 2026 reel/frame not recorded | Bank of America, N.A., as Collateral Agent | Suros Surgical Systems, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2026
Term ends Dec 7, 2026. No further fees fall due before then
Note
The 272 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
95
later US patents cite this one
That is top 10% of utility patents granted in 2009 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.